| Literature DB >> 34396408 |
Kristie L Connolly1, Michelle Pilligua-Lucas1, Carolina Gomez1, Allison C Costenoble-Caherty1, Anthony Soc1, Knashka Underwood1, Andrew N Macintyre2, Gregory D Sempowski2, Ann E Jerse1.
Abstract
Murine models of Neisseria gonorrhoeae lower reproductive tract infection are valuable systems for studying N. gonorrhoeae adaptation to the female host and immune responses to infection. These models have also accelerated preclinical testing of candidate therapeutic and prophylactic products against gonorrhea. However, because N. gonorrhoeae infection is restricted to the murine cervicovaginal region, there is a need for an in vivo system for translational work on N. gonorrhoeae pelvic inflammatory disease (PID). Here we discuss the need for well-characterized preclinical upper reproductive tract infection models for developing candidate products against N. gonorrhoeae PID, and report a refinement of the gonorrhea mouse model that supports sustained upper reproductive tract infection. To establish this new model for vaccine testing, we also tested the licensed meningococcal 4CMenB vaccine, which cross-protects against murine N. gonorrhoeae lower reproductive tract infection, for efficacy against N. gonorrhoeae in the endometrium and oviducts following transcervical or vaginal challenge. Published by Oxford University Press for the Infectious Diseases Society of America 2021.Entities:
Keywords: PID; antibiotics; gonorrhea; mouse; reproductive tract; vaccine; vaginal microbicides
Mesh:
Substances:
Year: 2021 PMID: 34396408 PMCID: PMC8365121 DOI: 10.1093/infdis/jiab211
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 7.759